Nicox
NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.
From 2004, Doliage laboratories were part of the first laboratories to make available the medical food supplement specially formulated to ophthalmology. Since then, we have always updated the composition of our products based on the latest. Scientific data Thus, Doliage laboratories were the first to associate lutein and omega 3 from 2005, which has since become the standard formulation micronutrition eyepiece. Since 2009, following the new releases, Doliage products were the first to bring the B vitamins Because Laboratories Doliage follow more closely the scientific studies, they have the most comprehensive market dietary supplements. All supplements Laboratories Doliage are manufactured in a pharmaceutical environment to ensure their quality.
Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.
EuPharmed s.r.l. develops and markets pharmaceutical products, over-the-counter products and parapharmaceuticals, nutraceuticals, and medical devices. It specializes in the ophthalmological sector. The company offers products for the treatment of various ocular pathologies and ophtalmic diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.